Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rashida Orlova, Konstantin Laktionov, Larisa Bolotina, Valeriy Vladimirovich Breder, Anastasia Danilova, Elena Filippova, Anna Kornietskaya, Mikhail Kramchaninov, Eugenia Kushniruk, Dilorom Latipova, Evgeny Ledin, Anastasia Mochalova, Fedor Vladimirovich Moiseenko, Tatiana Nikitina, Sergey Orlov, Svetlana Protsenko, Ksenia Sarantseva, Daniil Stroyakovskiy, Anna Zinkovskaya, Tatyana Ionova
Institutions: St Petersburg University, Russian Cancer Research Center NN Blokhin, Ministry of Health of the Russian Federation, P.A. Hertzen Moscow Oncology Research Institute, Moscow City Oncology Hospital №62, First Pavlov State Medical University of St. Petersburg, State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care, City Clinical Oncology Center, Institute of Oncology NN Petrov
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947273199